Shimadzu Europe
  • News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Digital edition
    • Archived issues
    • Free subscriptions
    • Media kit
    • Submit Press Release
  • White Papers
  • Events
  • Suppliers
  • E-Alert
  • Contact us
  • FREE newsletter subscription
  • Search
  • Menu Menu
Clinical Laboratory int.
  • Allergies
  • Cardiac
  • Gastrointestinal
  • Hematology
  • Microbiology
  • Microscopy & Imaging
  • Molecular Diagnostics
  • Pathology & Histology
  • Protein Analysis
  • Rapid Tests
  • Therapeutic Drug Monitoring
  • Tumour Markers
  • Urine Analysis

Archive for category: E-News

E-News

Spacemarkers novel AI method identifies locations, interactions among genes in and around tumours

, 1 June 2023/in E-News /by panglobal

SpaceMarkers, a new machine learning software developed by researchers at the Johns Hopkins Convergence Institute and the Johns Hopkins Kimmel Cancer Center, can identify molecular interactions among distinct types of cells in and around a tumour.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 0 0 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-06-01 08:10:252023-06-01 08:10:25Spacemarkers novel AI method identifies locations, interactions among genes in and around tumours

New ‘pangenome’ offers more inclusive view of human genome

, 1 June 2023/in E-News /by panglobal

When it was launched in April 2003, the Human Genome Project helped revolutionize biomedical research by providing scientists a reference map that allowed them to analyze DNA sequences for genetic clues to the origins of a host of diseases.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 0 0 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-06-01 08:08:152023-06-01 08:08:15New ‘pangenome’ offers more inclusive view of human genome
Exothera partners with Quantoom Biosciences, launches new business unit for development and production of RNA

Exothera partners with Quantoom Biosciences, launches new business unit for development and production of RNA

, 1 June 2023/in E-News /by panglobal

Exothera has partnered with Quantoom Biosciences to gain access to Quantoom’s Nfinity technology, a continuous production platform for RNA. The partnership will enable Exothera to be the first CDMO in the world to offer this off-the-shelf process for the continuous production of RNA as a service. Continuous manufacturing of RNA can provide significant advantages in […]

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/06/exothera.jpg 1277 1920 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-06-01 07:45:552023-06-01 07:48:55Exothera partners with Quantoom Biosciences, launches new business unit for development and production of RNA
biosynth logo

Biosynth strengthens peptide business with acquisition of Cambridge Research Biochemicals

, 1 June 2023/in E-News /by panglobal

Biosynth, a supplier of critical raw materials to the life science industry, has acquired Cambridge Research Biochemicals (CRB), a leading independent producer of custom-made peptide and antibody tools, based in the UK and supplying researchers in the pharmaceutical, life science and academic sectors.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/06/biosynth_logo.png 752 1114 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-06-01 07:43:102023-06-01 07:43:10Biosynth strengthens peptide business with acquisition of Cambridge Research Biochemicals
Bruker acquires ZONTAL to advance the digital lab transformation

Bruker acquires ZONTAL to advance the digital lab transformation

, 1 June 2023/in E-News /by panglobal

Bruker Corporation has acquired ZONTAL, an innovative platform provider for the digital transformation of the analytical laboratory, and for integrated biopharma technical data solutions. This acquisition further strengthens Bruker BioSpin’s Integrated Data Solutions (IDS) software division, which includes Mestrelab Research (www.mestrelab.com), Arxspan (www.arxspan.com) and Optimal (www.optimal-ltd.co.uk).

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/06/bruker_zontal.jpg 782 1920 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-06-01 07:41:072023-06-01 07:41:07Bruker acquires ZONTAL to advance the digital lab transformation
Scherm­afbeelding 2023 06 01 om 09.35.50

Oxford Nanopore, bioMérieux partner to develop infectious disease diagnostics

, 1 June 2023/in E-News /by panglobal

Oxford Nanopore Technologies, the company delivering a new generation of nanopore-based molecular sensing technology, and bioMérieux, a world leader in the field of in vitro diagnostics, are teaming up to improve health outcomes globally by exploring selected opportunities to bring nanopore sequencing to the infectious disease diagnostics market.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/06/Scherm­afbeelding-2023-06-01-om-09.35.50.png 416 746 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-06-01 07:36:522023-06-01 07:36:52Oxford Nanopore, bioMérieux partner to develop infectious disease diagnostics
Maxion Therapeutics awarded £2M Innovate UK funding to develop ion channel antibodies to treat autoimmune diseases

Maxion Therapeutics awarded £2M Innovate UK funding to develop ion channel antibodies to treat autoimmune diseases

, 1 June 2023/in E-News /by panglobal

Biotechnology company Maxion Therapeutics has been awarded a £2 million grant from Innovate UK, as part of its Biomedical Catalyst 2022 Round 2: Industry-led R&D funding competition. The funds will support the use of Maxion’s proprietary KnotBody platform www.maxiontherapeutics.com/#technology to develop antibodies to treat autoimmune diseases (AID) with high unmet clinical need.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/06/maxion.jpg 1038 1168 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-06-01 07:29:482023-06-01 07:29:48Maxion Therapeutics awarded £2M Innovate UK funding to develop ion channel antibodies to treat autoimmune diseases
thermo fisher

Thermo Fisher Scientific, Pfizer collaborate to expand accesss to next-generation sequencing-based cancer testing in more than 30 countries

, 31 May 2023/in E-News /by panglobal

Pfizer and Thermo Fisher Scientific have agreed to collaborate to help increase local access to next-generation sequencing (NGS)-based testing for lung and breast cancer patients in more than 30 countries across Latin America, Africa, the Middle East and Asia where advanced genomic testing has previously been limited or unavailable. Access to local NGS testing can […]

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/05/thermo-fisher.png 1080 1060 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-05-31 15:55:542023-06-01 07:25:01Thermo Fisher Scientific, Pfizer collaborate to expand accesss to next-generation sequencing-based cancer testing in more than 30 countries
Ken Hitchner

Sphere Fluidics appoints Kenneth Hitchner as Chairman of its Board of Directors

, 31 May 2023/in E-News /by panglobal

Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, has appointed Kenneth Hitchner, BA MBA, as Chairman of its Board of Directors. The announcement follows a series of appointments to the Company’s senior leadership team, as part of its ambitious global growth strategy.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/05/Ken-Hitchner.jpg 1050 750 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-05-31 15:53:492023-05-31 15:53:49Sphere Fluidics appoints Kenneth Hitchner as Chairman of its Board of Directors
Xyall and HALO AP

Xyall and Indica Labs forge global collaboration to transform precision oncology workflows

, 31 May 2023/in E-News /by panglobal

Xyall and Indica Labs have entered into a global strategic partnership designed to bridge the gap between histology and molecular pathology. It unites Xyall’s unique automated tissue dissection solutions with Indica Labs’ AI-powered, diagnostic digital pathology platform.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/05/Xyall-and-HALO-AP.jpg 1033 1920 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-05-31 15:50:592023-05-31 15:50:59Xyall and Indica Labs forge global collaboration to transform precision oncology workflows
Page 35 of 227«‹3334353637›»
Bio-Rad - Preparing for a Stress-free QC Audit

Latest issue of Clinical laboratory

November 2025

CLi Cover nov 2025
13 November 2025

New Chromsystems Product for Antiepileptic Drugs Testing

11 November 2025

Trusted analytical solutions for reliable results

10 November 2025

Chromsystems | Therapeutic Drug Monitoring by LC-MS/MS

Digital edition
All articles Archived issues

Free subscription

View more product news

Get our e-alert

The leading international magazine for Clinical laboratory Equipment for everyone in the Vitro diagnostics

Sign up today
  • News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Archived issues
    • Free subscriptions
    • Media kit
    • Submit Press Release
clinlab logo blackbg 1

Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com

PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.

Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settingsHide notification onlyCookie settings

Cookie and Privacy Settings



How we use cookies

We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.

Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.

We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.

We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.

.

Google Analytics Cookies

These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.

If you do not want us to track your visit to our site, you can disable this in your browser here:

.

Other external services

We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page

Google Webfont Settings:

Google Maps Settings:

Google reCaptcha settings:

Vimeo and Youtube videos embedding:

.

Privacy Beleid

U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.

Privacy policy
Accept settingsHide notification only

Subscribe now!

Become a reader.

Free subscription